Sigma Planning Corp Has $931,000 Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Sigma Planning Corp decreased its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 7.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 50,528 shares of the company’s stock after selling 4,087 shares during the quarter. Sigma Planning Corp’s holdings in Hims & Hers Health were worth $931,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of HIMS. Nisa Investment Advisors LLC boosted its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC boosted its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC boosted its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 3.4 %

HIMS opened at $27.60 on Thursday. The stock has a market cap of $5.93 billion, a PE ratio of 62.73 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $7.18 and a 1 year high of $30.44. The stock’s 50 day simple moving average is $19.25 and its 200-day simple moving average is $18.70.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the previous year, the business posted ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HIMS shares. TD Cowen boosted their target price on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Bank of America boosted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial boosted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.21.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 2,345 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the sale, the insider now owns 159,796 shares in the company, valued at $2,341,011.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock worth $15,987,230 over the last three months. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.